Popcorn Lung: the Discovery of a New Disease

Status Completed

Clinical Trial Summary

Recently, an epidemic of pulmonary disease has been recognized among workers in a popcorn factory in Jasper, Missouri. The exposure agent has not yet been identified, but suspects include butter flavoring and the powdered salt used in the mixing room. This disease resembles "Bronchiolitis Obliterans Syndrome", an illness that makes it difficult to breathe. Of the 117 workers studied, one year later, 25 subjects whom were working in the mixing room or in the microwave packaging area have had decreases in lung function seven times the norm for their age. Industrial hygiene experts revealed that dust concentrations of salt and other flavorings were much higher in the mixing room compared to the office and outdoor work areas. Recently, rats were exposed to vapors created by heating the butter flavor compound obtained from this plant. Six-hour exposure to vapors at very high concentration resulted in significant damage to the breathing apparatus. Thus, there is clinical, epidemiological, and animal toxicity data that appears to implicate some constituent present during the mixing of the butter flavoring, salt, and oil causing a form of obstructive airway disease that has been rapidly progressive in a number of workers. It is not clear what the pathophysiologic nature of this entity is, though it resembles Bronchiolitis Obliterans Syndrome. It is not known what the long term consequence of this will be on the active workers, nor is it clear whether preventive measures taken to reduce exposures in the mixing room and elsewhere in the plant are going to be effective.

Clinical Trial Description

n/a

Study Design

Observational Model: Defined Population, Time Perspective: Longitudinal

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00027235
Study type	Observational
Source	National Center for Research Resources (NCRR)
Contact
Status	Completed
Phase	N/A

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04119115` - Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Active, not recruiting	`NCT04559581` - Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
Recruiting	`NCT05151640` - INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
Recruiting	`NCT02543073` - MSC for Treatment of Interstitial Lung Disease After Allo-HSCT	Phase 1/Phase 2
Completed	`NCT02251964` - Rituximab in Interstitial Pneumonitis	Phase 2/Phase 3
Terminated	`NCT01432080` - Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant	Phase 2
Completed	`NCT01442779` - Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis	Phase 2
Recruiting	`NCT05596760` - Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers	N/A
Recruiting	`NCT05866198` - Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation	N/A
Active, not recruiting	`NCT05321082` - A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)	Phase 3
Completed	`NCT04016168` - Idiopathic Pulmonary Fibrosis and Serum Bank
Recruiting	`NCT00258583` - Dorothy P. and Richard P. Simmons Center for ILD Research Registry
Recruiting	`NCT05855109` - Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
Completed	`NCT05719233` - Assessment of Neuropsychiatric Function in Patients With Interstitial Lung Disease
Recruiting	`NCT04159129` - Effects of Pulmonary Rehabilitation on Walking Speed in Patients With COPD or ILD Patients
Completed	`NCT03313180` - A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis	Phase 3
Completed	`NCT05065190` - A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis	Phase 3
Completed	`NCT03136120` - Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease
Recruiting	`NCT04930666` - BREATHE ALD: A Shared Decision-Making Intervention for Adults With Advanced Lung Disease
Recruiting	`NCT05503030` - Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients